AR064026A1 - Derivados de azacicloalcanos como inhibidores de estearoil-coenzima a delta-9 desaturasa - Google Patents

Derivados de azacicloalcanos como inhibidores de estearoil-coenzima a delta-9 desaturasa

Info

Publication number
AR064026A1
AR064026A1 ARP070105302A ARP070105302A AR064026A1 AR 064026 A1 AR064026 A1 AR 064026A1 AR P070105302 A ARP070105302 A AR P070105302A AR P070105302 A ARP070105302 A AR P070105302A AR 064026 A1 AR064026 A1 AR 064026A1
Authority
AR
Argentina
Prior art keywords
alkyl
optionally substituted
group
heteroaryl
independently
Prior art date
Application number
ARP070105302A
Other languages
English (en)
Original Assignee
Merck Frosst Canada Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Frosst Canada Ltd filed Critical Merck Frosst Canada Ltd
Publication of AR064026A1 publication Critical patent/AR064026A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

Son de utilidad para la prevencion y tratamiento de afecciones relacionadas con la síntesis y metabolismo anormales de lípidos, incluidas enfermedades cardiovasculares, tales como aterosclerosis; obesidad; diabetes; enfermedad neurologica; síndrome metabolico; resistencia a insulina; y esteatosis hepática. Reivindicacion 1: Un compuesto de la formula estructural 1: o una sal farmacéuticamente aceptable de la misma; en la que: q es 0 o 1; r es 0 o 1; Z es O, S, o NR4; X-Y es N-C(O), N-CRaRb, CR14-O, CR14-S(O)0-2, o CR13-CRaRb; Ra y Rb son cada uno independientemente hidrogeno o alquilo C1-3, en los que el alquilo está opcionalmente sustituido con de uno a tres sustituyentes que se seleccionan independientemente a partir de fluor e hidroxi; W es heteroarilo que se selecciona del grupo constituido por el grupo de formulas (2); R1 es heteroarilo que se selecciona del grupo constituido por el grupo de formulas (3) en el que RC es -(CH2)mCO2H, -(CH2)mCO2alquilo C1-3, -(CH2)m-Z- (CH2)pCO2H, o -(CH2)m-Z-(CH2)pCO2alquilo C1-3; en el que cualquier átomo de carbono de los grupos metileno (CH2) de (CH2)m o (CH2)p está opcionalmente sustituido con un hidroxi, un amino o uno u dos átomos de fluor; y en el que dicho anillo heteroarilo R1 está opcionalmente sustituido con un sustituyente que se selecciona independientemente a partir del grupo constituido por ciano, halogeno, alquilo C1-4, alcoxi C1-4, alquiltio C1-4, alquilsulfonilo C1-4, y trifluorometilo; cada R2 se selecciona independientemente a partir del grupo constituido por: hidrogeno, halogeno, hidroxi, ciano, amino, nitro, alquilo C1-4, opcionalmente sustituido con de uno a cinco átomos de fluor, alcoxi C1-4, opcionalmente sustituido con de uno a cinco átomos de fluor, alquiltio C1-4, opcionalmente sustituido con de uno a cinco átomos de fluor, alquil C1-4 sulfonilo, carboxi, alquiloxi C1-4 carbonilo, y alquil C1-4 carbonilo; Ar es fenilo, naftilo, o heteroarilo opcionalmente sustituido con de uno a cinco sustituyentes R3; cada R3 se selecciona Independientemente a partir del grupo constituido por: alquilo C1-6, alquenilo C2-6, (CH2)n-fenilo, (CH2)n-naftilo, (CH2)n-heteroarilo, (CH2)n-heterociclilo, (CH2)n-cicloalquilo 3-7, halogeno, nitro, (CH2)nOR4, (CH2)nN(R4)2, (CH2)nC:::N, (CH2)nCO2R4, (CH2)NR4SO2R4, (CH2)nSO2N(R4)2, (CH2)nS(O)0-2R4, (CH2)nNR4C(O)N(R4)2, (CH2)nC(O)N(R4)2, (CH2)nNR4C(O)R4, (CH2)nNR4CO2R4, (CH2)nC(O)R4, O(CH2)nC(O)N(R4)2, (CH2)s-Z-(CH2)t-fenilo, (CH2)s-Z-(CH2)t- naftilo, (CH2)s-Z-(CH2)t-heteroarilo, (CH2)s-Z-(CH2)t-heterociclilo, (CH2)s-Z-(CH2)t-cicIoalquilo C3-7, (CH2)s-Z-(CH2)t-OR4, (CH2)s-Z-(CH2)t-N(R4)2, (CH2)s-Z-(CH2)t-NR4SO2R4, (CH2)s-Z-(CH2)t-C:::N, (CH2)s-Z-(CH2)t-CO2R4, (CH2)s-Z-(CH2)t-SO2N(R4)2, (CH2)s-Z-(CH2)t-S(O)0-2R4, (CH2)s-Z-(CH2)t-NR4C(O)N(R4)2, (CH2)s-Z-(CH2)t-C(O)N(R4)2, (CH2)s-Z-(CH2)t-NR4C(O)R4, (CH2)s-Z-(CH2)t-NR4CO2R4, (CH2)s-Z-(CH2)t-C(O)R4, CF3, CH2CF3, OCF3, y OCH2CF3; en el que fenilo, naftilo, heteroarilo, cicloalquilo, y heterociclilo están opcionalmente sustituidos con de uno a tres sustituyentes que se seleccionan independientemente a partir de halogeno, hidroxi, alquilo C1-4, trifluorometilo, y alcoxi C1-4, opcionalmente sustituido con de uno a cinco átomos de fluor y en el que cualquier átomo de carbono de un metileno (CH2) de R3 está opcionalmente sustituido con de uno a dos grupos que se seleccionan independientemente a partir de fluor, hidroxi, y alquilo C1-4; o dos sustituyentes cuando están en ci mismo grupo metileno (CH2) se toman conjuntamente con el átomo de carbono al que están unidos formando un grupo ciclopropilo; cada R4 se selecciona independientemente a partir del grupo constituido por hidrogeno, alquilo C1-6, (CH2)n-fenilo, (CH2)n- heteroarilo, (CH2)n-naftilo, y (CH2)ncicloalquilo C3-7, en el que alquilo, fenilo, heteroarilo, y cicloalquilo están opcionalmente sustituidos con de uno a tres grupos que se seleccionan independientemente a partir de halogeno, alquilo C1-4 y alcoxi C1-4, o dos grupos R4 junto con el átomo al que están unidos forman un sistema anular cíclico monociclico o bicíclico de 4 a 8 miembros que opcionalmente contiene un heteroátomo adicional que se selecciona a partir de O, S, NH, y Nalquilo C1-4; R5, R6, R7, R8, R9, R10, R11, y R12 son cada uno independientemente hidrogeno, fluor, o alquilo C1-3, en los que el alquilo está opcionalmente sustituido con de uno a tres sustituyentes que se seleccionan independientemente a partir de fluor e hidroxi; R13 es hidrogeno, alquilo C1-3, fluor, o hidroxi; cada R14 es hidrogeno o alquilo C1-3; cada m es independientemente un numero entero de 0 a 4; cada p es independientemente un numero entero de 1 a 3; cada n es independientemente un numero entero de 0 a 2; cada s es independientemente un numero entero de 1 a 3; y cada t es independientemente un numero entero de 1 a 3.
ARP070105302A 2006-12-01 2007-11-29 Derivados de azacicloalcanos como inhibidores de estearoil-coenzima a delta-9 desaturasa AR064026A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87221606P 2006-12-01 2006-12-01
US89890007P 2007-02-01 2007-02-01

Publications (1)

Publication Number Publication Date
AR064026A1 true AR064026A1 (es) 2009-03-04

Family

ID=39467388

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070105302A AR064026A1 (es) 2006-12-01 2007-11-29 Derivados de azacicloalcanos como inhibidores de estearoil-coenzima a delta-9 desaturasa

Country Status (24)

Country Link
US (1) US8063224B2 (es)
EP (1) EP2099793B1 (es)
JP (1) JP5050061B2 (es)
KR (1) KR20090086623A (es)
AR (1) AR064026A1 (es)
AT (1) ATE543816T1 (es)
AU (1) AU2007327276B2 (es)
BR (1) BRPI0719702A2 (es)
CA (1) CA2670703C (es)
CL (1) CL2007003440A1 (es)
CO (1) CO6190521A2 (es)
CR (1) CR10858A (es)
EA (1) EA200970524A1 (es)
EC (1) ECSP099375A (es)
GT (1) GT200900144A (es)
IL (1) IL198824A0 (es)
MA (1) MA31017B1 (es)
MX (1) MX2009005713A (es)
NO (1) NO20092469L (es)
PE (1) PE20081199A1 (es)
SV (1) SV2009003275A (es)
TN (1) TN2009000212A1 (es)
TW (1) TW200826936A (es)
WO (1) WO2008064474A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001062954A2 (en) * 2000-02-24 2001-08-30 Xenon Genetics, Inc. Stearoyl-coa desaturase to identify triglyceride reducing therapeutic agents
WO2007134457A1 (en) * 2006-05-22 2007-11-29 Merck Frosst Canada Ltd. Cyclic amine derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
AU2007260527A1 (en) * 2006-06-12 2007-12-21 Merck Frosst Canada Ltd. Azetidine derivatives as inhibitors of stearoyl-coenzyme A delta-9 desaturase
EP2032570A4 (en) 2006-06-13 2010-10-27 Merck Frosst Canada Ltd AZACYCLOPENTATE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME-A-DELTA-9-DESATURASE
WO2008017161A1 (en) * 2006-08-09 2008-02-14 Merck Frosst Canada Ltd. Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
AR064965A1 (es) 2007-01-26 2009-05-06 Merck Frosst Canada Inc Derivados de azacicloalcanos como inhibidores de estearoil - coenzima a delta -9 desaturasa
WO2008128335A1 (en) * 2007-04-20 2008-10-30 Merck Frosst Canada Ltd. Novel heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase
AU2008253512A1 (en) * 2007-05-23 2008-11-27 Merck Frosst Canada Ltd. Bicyclic heteroaromatic compounds as inhibitors of stearoyl-coenzyme A delta-9 desaturase
WO2008157844A1 (en) 2007-06-21 2008-12-24 Forest Laboratories Holdings Limited Novel piperazine derivatives as inhibitors of stearoyl-coa desaturase
UA98799C2 (ru) * 2007-07-19 2012-06-25 Такеда Фармасьютикал Компани Лимитед Твердый препарат, включающий алоглиптин и гидрохлорид метформина
WO2009012573A1 (en) * 2007-07-20 2009-01-29 Merck Frosst Canada Ltd. Bicyclic heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase
AU2009290089A1 (en) * 2008-09-08 2010-03-11 Merck Frosst Canada Ltd. Heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase
US9168248B2 (en) 2009-02-17 2015-10-27 Merck Canada Inc. Spiro compounds useful as inhibitors of stearoyl-coenzyme A delta-9 desaturase
JP2012518603A (ja) * 2009-02-23 2012-08-16 メルク カナダ インコーポレイテッド ステアロイル−コエンザイムａデルタ−９デサチュラーゼの阻害剤としての複素環誘導体
WO2010108268A1 (en) * 2009-03-23 2010-09-30 Merck Frosst Canada Ltd. Heterocyclic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase
WO2011011872A1 (en) 2009-07-28 2011-02-03 Merck Frosst Canada Ltd. Novel spiro compounds useful as inhibitors of stearoyl-coenzyme a delta-9 desaturase
KR20130100903A (ko) 2010-04-28 2013-09-12 바이엘 크롭사이언스 아게 살진균제로서의 케토헤테로아릴피페리딘 및 케토헤테로아릴피페라진 유도체
CA2825684C (en) * 2011-01-28 2021-11-23 4Sc Discovery Gmbh Il17 and ifn-gamma inhibition for the treatment of autoimmune inflammation
CA2850836A1 (en) 2011-10-15 2013-04-18 Genentech, Inc. Methods of using scd1 antagonists
WO2013062882A1 (en) * 2011-10-26 2013-05-02 Merck Canada Inc. Scd inhibitors for the treatment of hcv
WO2013134546A1 (en) 2012-03-07 2013-09-12 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
CN104768549A (zh) 2012-05-22 2015-07-08 耶路撒冷希伯来大学的益生研究开发有限公司 未分化细胞的选择性抑制剂
WO2018081167A1 (en) * 2016-10-24 2018-05-03 Yumanity Therapeutics Compounds and uses thereof
US10973810B2 (en) * 2017-01-06 2021-04-13 Yumanity Therapeutics, Inc. Methods for the treatment of neurological disorders
WO2019084157A1 (en) 2017-10-24 2019-05-02 Yumanity Therapeutics, Inc. COMPOUNDS AND USES THEREOF

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1595923A1 (de) * 1965-02-20 1969-11-27 Merck Ag E 1-Aralkyl-4-(thiazolyl-2)-piperazine und Verfahren zu ihrer Herstellung
DK0876366T3 (da) 1996-01-15 2001-11-05 Janssen Pharmaceutica Nv Angiogenese-inhiberende pyridazinaminer
US20050119251A1 (en) * 2001-12-21 2005-06-02 Jian-Min Fu Nicotinamide derivatives and their use as therapeutic agents
ATE555789T1 (de) 2003-07-30 2012-05-15 Xenon Pharmaceuticals Inc Pyridazinderivate und deren verwendung als therapeutische mittel
US7754711B2 (en) 2003-07-30 2010-07-13 Xenon Pharmaceuticals Inc. Pyridazine derivatives and their use as therapeutic agents
US7345043B2 (en) * 2004-04-01 2008-03-18 Miikana Therapeutics Inhibitors of histone deacetylase
TW200624427A (en) 2004-09-20 2006-07-16 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as therapeutic agents
MX2007003329A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y biciclicos y su uso como inhibidores de estearoil-coa-desaturasa (scd).
WO2006034279A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as therapeutic agents
EP2316458A1 (en) 2004-09-20 2011-05-04 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
US7951805B2 (en) 2004-09-20 2011-05-31 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
US7767677B2 (en) * 2004-09-20 2010-08-03 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
AR051026A1 (es) * 2004-09-20 2006-12-13 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
JP4958785B2 (ja) 2004-09-20 2012-06-20 ゼノン・ファーマシューティカルズ・インコーポレイテッド 複素環誘導体およびステアロイル−ＣｏＡデサチュラーゼインヒビターとしてのそれらの使用
GT200600046A (es) 2005-02-09 2006-09-25 Terapia de combinacion
WO2006125181A2 (en) 2005-05-19 2006-11-23 Xenon Pharmaceuticals Inc. Piperidine derivatives and their use as stearoyl-coa desaturase modulators
US20090099200A1 (en) * 2005-06-09 2009-04-16 Chun Sing Li Azacyclohexane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
JP2009501733A (ja) 2005-07-20 2009-01-22 メルク フロスト カナダ リミテツド ステアロイルコエンザイムａデルタ−９デサチュラーゼの阻害剤としてのヘテロ芳香族化合物
EP1934205A4 (en) 2005-10-05 2010-06-02 Merck Frosst Canada Ltd SUBSTITUTED QUINOLINES AS INHIBITORS OF LEUCOTRIENE BIOSYNTHESIS
JP2009515839A (ja) 2005-11-15 2009-04-16 メルク フロスト カナダ リミテツド ステアロイル−ＣｏＡデルタ−９デサチュラーゼ阻害剤としてのアザシクロヘキサン誘導体
US7799787B2 (en) 2005-12-20 2010-09-21 Merck Frosst Canada Ltd. Heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase
WO2007134457A1 (en) 2006-05-22 2007-11-29 Merck Frosst Canada Ltd. Cyclic amine derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
AU2007260527A1 (en) 2006-06-12 2007-12-21 Merck Frosst Canada Ltd. Azetidine derivatives as inhibitors of stearoyl-coenzyme A delta-9 desaturase
EP2032570A4 (en) 2006-06-13 2010-10-27 Merck Frosst Canada Ltd AZACYCLOPENTATE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME-A-DELTA-9-DESATURASE
WO2008017161A1 (en) 2006-08-09 2008-02-14 Merck Frosst Canada Ltd. Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
AU2007312866A1 (en) 2006-10-20 2008-04-24 Merck Frosst Canada Ltd. Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme A delta-9 desaturase
AR064965A1 (es) * 2007-01-26 2009-05-06 Merck Frosst Canada Inc Derivados de azacicloalcanos como inhibidores de estearoil - coenzima a delta -9 desaturasa

Also Published As

Publication number Publication date
JP5050061B2 (ja) 2012-10-17
PE20081199A1 (es) 2008-10-19
CA2670703C (en) 2012-05-15
CL2007003440A1 (es) 2008-04-04
MA31017B1 (fr) 2009-12-01
ECSP099375A (es) 2009-07-31
EP2099793A1 (en) 2009-09-16
CA2670703A1 (en) 2008-06-05
MX2009005713A (es) 2009-06-08
CR10858A (es) 2009-06-25
BRPI0719702A2 (pt) 2013-12-17
US8063224B2 (en) 2011-11-22
TN2009000212A1 (en) 2010-10-18
KR20090086623A (ko) 2009-08-13
JP2010510993A (ja) 2010-04-08
US20080132542A1 (en) 2008-06-05
EA200970524A1 (ru) 2009-12-30
SV2009003275A (es) 2009-11-18
AU2007327276B2 (en) 2011-06-09
NO20092469L (no) 2009-08-27
IL198824A0 (en) 2010-02-17
TW200826936A (en) 2008-07-01
ATE543816T1 (de) 2012-02-15
AU2007327276A1 (en) 2008-06-05
EP2099793B1 (en) 2012-02-01
EP2099793A4 (en) 2010-12-29
GT200900144A (es) 2011-06-23
WO2008064474A1 (en) 2008-06-05
CO6190521A2 (es) 2010-08-19

Similar Documents

Publication Publication Date Title
AR064026A1 (es) Derivados de azacicloalcanos como inhibidores de estearoil-coenzima a delta-9 desaturasa
AR064965A1 (es) Derivados de azacicloalcanos como inhibidores de estearoil - coenzima a delta -9 desaturasa
CR9267A (es) Derivados de quinazolina para el tratamiento de la tuberculosis latente
RU2018121499A (ru) Гипоксантины в качестве ингибиторов убиквитин-специфической протеазы 1
AR082763A1 (es) Derivados de piperidinona como inhibidores mdm2 para el tratamiento de cancer
AR127309A2 (es) Derivados de piridazinona
JP2016506961A5 (es)
CO5251381A1 (es) Derivados de adamantano, un proceso para su preparacion y composiciones farmaceuticas que los contienen
AR062928A1 (es) Inhibidores de la actividad quinasa utiles en el tratamiento de trastornos mediados por mecanismos de ikk2
AR067396A1 (es) Compuesto derivado de imidazo(1,2-a)piridin-2-ilmetil piperidina sustituida sal hidrocloruro del mismo uso del compuesto o de la sal hidrocloruro para la preparacion de un medicamento y composiciones farmaceuticas que los comprende
AR057770A1 (es) Inhibidores de la p38-map-quinasa y composicion farmaceutica
AR066669A1 (es) Derivados de imidazolona como inhibidores de bencimidazolona quimasa. composiciones farmaceuticas.
EA200602060A1 (ru) Производные пирролидин-2-она и пиперидин-2-она, используемые в качестве ингибиторов 11-бета-гидроксистероид-дегидрогеназы
RU2014103587A (ru) Производные циклических аминов в качестве антагонистов рецептора ер4
AR079689A1 (es) Derivados de imidazo[1,2a]piridina, composiciones farmaceuticas que los comprenden y uso de los mismos en trastornos mieloproliferativos, leucemia y enfermedades inmunologicas e inflamatorias.
AR067886A1 (es) Derivados de acido azabifenilaminobenzoico
AR072249A1 (es) Inhibidores de amida hidrolasa de acido graso. usos. metodos.
RU2007148504A (ru) Индановые производные в качестве модуляторов ионных каналов
AR074426A1 (es) Compuesto de n-(((1s,4s,6s)-3-(2-piridinilcarbonil)3-azabiciclo (4,1.0)hept-4-il) metil)-2-heteroarilamina, su uso para la prepracion de un medicamento para el tratamiento de una enfermedad que requiere un antagonista de un receptor de orexina humana y composicion farmaceutica que lo comprende
ATE390421T1 (de) Aminoheterocyclen als vr-1 antagonisten zur behandlung von schmerzen
AR069796A1 (es) Derivados de bencimidazol, sustituido por carboxilo o por hidroxilo, proceso para prepararlos y composiciones farmaceuticas que los contienen
BR112012001031A8 (pt) Compostos espiro amino adequados para o tratamento de inter alia distúrbios do sono e toxicodependência
RU2012142171A (ru) Ингибиторы катехол-о-метилтрансферазы и их применение в лечении психических расстройств
AR050341A1 (es) Compuestos derivados de piperidina, composicion farmaceutica en base al compuesto y su uso para preparar medicamentos
AR077819A1 (es) Compuestos heterociclicos antagonistas de esfingosina -1-fosfato (sip)

Legal Events

Date Code Title Description
FA Abandonment or withdrawal